Search - tctmd.com

Displaying 61 - 80 of 152

Sort: Relevancy | Date

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Conference News AHA 2021

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

Michael O'Riordan

November 13, 2021

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2021

Shelley Wood

July 05, 2021

News Daily News

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

Michael O'Riordan

June 18, 2021

News Conference News EAS 2021

Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI

Michael O'Riordan

June 07, 2021

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

News Conference News EHRA 2021

RACE 3: Effects Wane for Targeted Therapy in Early AF, HF

Todd Neale

April 26, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Conference News EAS 2020

Just One-Third of European Patients Get to LDL Cholesterol Goals

Michael O'Riordan

October 13, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Daily News

More Insights Into AAA Genetics Spur New Questions on Screening

Caitlin E. Cox

September 29, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Conference News AHA 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Caitlin E. Cox

November 19, 2019

News Conference News AHA 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Shelley Wood

November 18, 2019

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

Advertisement

British Medical Groups Express Concern About Inclisiran Rollout

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

TCTMD’s Top 10 Most Popular Stories for June 2021

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

RACE 3: Effects Wane for Targeted Therapy in Early AF, HF

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Approves Evinacumab for Rare Homozygous FH

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Just One-Third of European Patients Get to LDL Cholesterol Goals

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

More Insights Into AAA Genetics Spur New Questions on Screening

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content